scholarly article | Q13442814 |
P2093 | author name string | R Vogel | |
J Eng | |||
D A D'Alessio | |||
J W Ensinck | |||
D Koerker | |||
E Laschansky | |||
R Prigeon | |||
P2860 | cites work | Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans | Q27865308 |
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo | Q27999767 | ||
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum | Q28117412 | ||
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal | Q34147299 | ||
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine | Q34180164 | ||
Insulin Secretion in Response to Glycemic Stimulus: Relation of Delayed Initial Release to Carbohydrate intolerance in Mild Diabetes Mellitus* | Q34267205 | ||
Glucagon-like peptide-1 is a physiological incretin in rat | Q34662409 | ||
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate | Q36396952 | ||
Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose | Q37006231 | ||
Glucagon and the glucagon-like peptides | Q37945757 | ||
New developments in the incretin concept | Q39832287 | ||
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects* | Q40329405 | ||
Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus | Q40342100 | ||
Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas | Q40920945 | ||
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. | Q41527377 | ||
Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. | Q41543796 | ||
A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinol | Q41675896 | ||
Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose | Q41902943 | ||
Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. | Q42492827 | ||
Glucagon-like peptide 1: a potent glycogenic hormone | Q42496184 | ||
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). | Q42574446 | ||
Glucagon-like peptide-1 7-36: a physiological incretin in man. | Q43623564 | ||
Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4 | Q43684539 | ||
Use of benzamidine as a proteolytic inhibitor in the radioimmunoassay of glucagon in plasma | Q44793381 | ||
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus | Q45306841 | ||
Studies of a Simplified Plasma Insulin Immunoassay Using Cellulose Powder | Q46429425 | ||
Early and late insulin response as predictors of NIDDM in Pima Indians with impaired glucose tolerance. | Q51591219 | ||
Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. | Q51596078 | ||
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. | Q51599426 | ||
Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. | Q51600133 | ||
Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. | Q51601217 | ||
Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects | Q51606971 | ||
Nutrient and hormonal regulation of the threshold of glucose-stimulated insulin secretion in isolated rat pancreases. | Q51624645 | ||
Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). | Q51630012 | ||
The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. | Q52870668 | ||
Glucagonlike peptide 1: a newly discovered gastrointestinal hormone | Q58449144 | ||
Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes | Q68145371 | ||
Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus | Q68917267 | ||
Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide | Q69511007 | ||
Intestinal Factors in the Control of Insulin Secretion | Q71162152 | ||
Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide | Q72390484 | ||
Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle | Q72572861 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | glucose | Q37525 |
glycobiology | Q899224 | ||
P304 | page(s) | 133-138 | |
P577 | publication date | 1996-01-01 | |
P1433 | published in | Journal of Clinical Investigation | Q3186904 |
P1476 | title | Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons | |
P478 | volume | 97 |
Q48183718 | Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice |
Q34560507 | Alpha cell function in health and disease: influence of glucagon-like peptide-1. |
Q37174896 | CNS GLP-1 regulation of peripheral glucose homeostasis |
Q37212333 | Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides |
Q36479829 | Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms |
Q37031078 | Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects |
Q54068522 | Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. |
Q42136958 | Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis |
Q33869732 | Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes |
Q38356895 | Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti |
Q35545683 | Enhancing Incretin Action for the Treatment of Type 2 Diabetes |
Q36846123 | Exenatide can reduce glucose independent of islet hormones or gastric emptying |
Q39801749 | Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans |
Q40420025 | Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion |
Q43638669 | Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers |
Q44665356 | Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system |
Q35360690 | GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification |
Q36249759 | GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel |
Q79387626 | Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia |
Q34401791 | Glucagon-like peptide 1(GLP-1) in biology and pathology |
Q35772029 | Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes |
Q52522147 | Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. |
Q74642726 | Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide |
Q38225693 | Incretins: their physiology and application in the treatment of diabetes mellitus. |
Q47295180 | Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. |
Q26749196 | Is GLP-1 a hormone: Whether and When? |
Q35624667 | Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors |
Q33184111 | Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum |
Q44594452 | Long-term effects of high dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: comparison among barley, rice, and cornstarch |
Q33634407 | Meal-anticipatory glucagon-like peptide-1 secretion in rats. |
Q40036350 | New ways in which GLP-1 can regulate glucose homeostasis |
Q34286456 | Nonhuman primates and other animal models in diabetes research |
Q41104121 | Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness |
Q26825393 | Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block |
Q54046117 | Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39). |
Q37061286 | Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion |
Q42492321 | Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice |
Q36902183 | The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? |
Q33776092 | The incretin system and cardiometabolic disease |
Q37913523 | The role of dysregulated glucagon secretion in type 2 diabetes |
Q35251016 | The role of gut hormones in glucose homeostasis |
Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
Q36269671 | Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches |
Q35680897 | β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity |